The efficacy of standard antidepressants is limited for many patients with mood disorders
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …

The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a
promising new strategy with potential for developing novel treatments for a variety of central …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery,
filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique …

Severe psychiatric disorders such as schizophrenia are related to cognitive and negative
symptoms, which often are resistant to current treatment approaches. The glutamatergic …

Glutamate is the primary excitatory neurotransmitter in the brain and plays critical roles in all
aspects of neuronal function. Disruption of normal glutamate transmission has been …

Accumulating data indicate that the glutamate system is disrupted in major depressive
disorder (MDD), and recent clinical research suggests that ketamine, an antagonist of the N …

The discovery of robust antidepressant effects of ketamine in refractory patients has led to
increasing focus on agents targeting glutamatergic signaling as potential novel …

Metabotropic glutamate (mGlu) receptors respond to glutamate, the major excitatory
neurotransmitter in the mammalian brain, mediating a modulatory role that is critical for …

Major depression is a highly prevalent disorder and is predicted to be the second leading
cause of disease burden by 2020. Although many antidepressant drugs are currently …